Ionis Pharmaceuticals, Inc. (IONS) Q4 FY25 Earnings Call

Commercial momentum is strong, but 2026 guidance anticipates Tringolza revenue pressure before the SHTG launch.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length59 minutes
EPS$-1.41
EPS consensus$-1.31
Revenue$203.3M
Revenue consensus$156.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All IONS earnings ยท Back to IONS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.